Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma. A leading cause of blindness with no cure, glaucoma is a disease of the eye that is typically characterized by structural evidence of optic nerve damage, vision loss and consistently elevated intraocular pressure, or IOP. The Company’s lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic that Inotek rationally designed to lower IOP by restoring the eye’s natural pressure control mechanism. The Company believes that by restoring the natural function of the trabecular meshwork (TM) and this outflow path, rather than changing the fundamental dynamics of pressure regulation in the eye, trabodenoson’s mechanism of action should result in a lower risk of unintended side effects and long term safety issues versus other mechanisms of action.